// App-Quantinova.ai

: PUR1800 (RV1162), A novel narrow spectrum kinase inhibitor, but not Fluticasone, reduces TNFa-induced cytokine release by primary bronchial epithelial cells from healthy volunteers and COPD patients

Researchers

Presenter

  • Aidan Curran

Principal Investigators

  • Catherine Charron

  • Paul Russell

  • David Hava

Medical Centers

  • Pulmatrix Inc, Lexington, United States of America

  • Pfizer Ltd, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • Mitogen-activated protein kinase

  • p38 Mitogen-activated protein kinases

  • C-X-C motif chemokine ligand 8

  • Interleukin 6

  • Spleen tyrosine kinase

Drug/Treatment

  • Fluticasone propionate

  • Fluticasone furoate

  • PUR 1800

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved